These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 20556668)

  • 1. Targeting the vasoprotective axis of the renin-angiotensin system: a novel strategic approach to pulmonary hypertensive therapy.
    Bradford CN; Ely DR; Raizada MK
    Curr Hypertens Rep; 2010 Aug; 12(4):212-9. PubMed ID: 20556668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension.
    Ferreira AJ; Shenoy V; Yamazato Y; Sriramula S; Francis J; Yuan L; Castellano RK; Ostrov DA; Oh SP; Katovich MJ; Raizada MK
    Am J Respir Crit Care Med; 2009 Jun; 179(11):1048-54. PubMed ID: 19246717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research Progress on Pulmonary Arterial Hypertension and the Role of the Angiotensin Converting Enzyme 2-Angiotensin-(1-7)-Mas Axis in Pulmonary Arterial Hypertension.
    Zhang F; Chen A; Pan Y; Wang X; Xu Y; Desai AA; Tang H; Han Y
    Cardiovasc Drugs Ther; 2022 Apr; 36(2):363-370. PubMed ID: 33394361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-Acetyl-Seryl-Asparyl-Lysyl-Proline regulates lung renin angiotensin system to inhibit epithelial-mesenchymal transition in silicotic mice.
    Li S; Li Y; Zhang Y; Li S; Zhang M; Jin F; Wei Z; Yang Y; Gao X; Mao N; Ge X; Xu H; Yang F
    Toxicol Appl Pharmacol; 2020 Dec; 408():115255. PubMed ID: 33007385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension.
    Shenoy V; Ferreira AJ; Qi Y; Fraga-Silva RA; Díez-Freire C; Dooies A; Jun JY; Sriramula S; Mariappan N; Pourang D; Venugopal CS; Francis J; Reudelhuber T; Santos RA; Patel JM; Raizada MK; Katovich MJ
    Am J Respir Crit Care Med; 2010 Oct; 182(8):1065-72. PubMed ID: 20581171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic modulation of ACE2 expression.
    Soler MJ; Barrios C; Oliva R; Batlle D
    Curr Hypertens Rep; 2008 Oct; 10(5):410-4. PubMed ID: 18775121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary diseases.
    Tan WSD; Liao W; Zhou S; Mei D; Wong WF
    Curr Opin Pharmacol; 2018 Jun; 40():9-17. PubMed ID: 29288933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three key proteases--angiotensin-I-converting enzyme (ACE), ACE2 and renin--within and beyond the renin-angiotensin system.
    Guang C; Phillips RD; Jiang B; Milani F
    Arch Cardiovasc Dis; 2012; 105(6-7):373-85. PubMed ID: 22800722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Losartan attenuates chronic cigarette smoke exposure-induced pulmonary arterial hypertension in rats: possible involvement of angiotensin-converting enzyme-2.
    Han SX; He GM; Wang T; Chen L; Ning YY; Luo F; An J; Yang T; Dong JJ; Liao ZL; Xu D; Wen FQ
    Toxicol Appl Pharmacol; 2010 May; 245(1):100-7. PubMed ID: 20178811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral delivery of Angiotensin-converting enzyme 2 and Angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension.
    Shenoy V; Kwon KC; Rathinasabapathy A; Lin S; Jin G; Song C; Shil P; Nair A; Qi Y; Li Q; Francis J; Katovich MJ; Daniell H; Raizada MK
    Hypertension; 2014 Dec; 64(6):1248-59. PubMed ID: 25225206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human angiotensin-converting enzyme 2 as a new renin-angiotensin system peptidase for heart failure therapy.
    Oudit GY; Penninger JM
    Curr Heart Fail Rep; 2011 Sep; 8(3):176-83. PubMed ID: 21611889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACE2, a promising therapeutic target for pulmonary hypertension.
    Shenoy V; Qi Y; Katovich MJ; Raizada MK
    Curr Opin Pharmacol; 2011 Apr; 11(2):150-5. PubMed ID: 21215698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opportunities for targeting the angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor pathway in hypertension.
    Fraga-Silva RA; Ferreira AJ; Dos Santos RA
    Curr Hypertens Rep; 2013 Feb; 15(1):31-8. PubMed ID: 23212695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACE2: a new target for cardiovascular disease therapeutics.
    Raizada MK; Ferreira AJ
    J Cardiovasc Pharmacol; 2007 Aug; 50(2):112-9. PubMed ID: 17703127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrapulmonary activation of the angiotensin-converting enzyme type 2/angiotensin 1-7/G-protein-coupled Mas receptor axis attenuates pulmonary hypertension in Ren-2 transgenic rats exposed to chronic hypoxia.
    Hampl V; Herget J; Bíbová J; Baňasová A; Husková Z; Vaňourková Z; Jíchová Š; Kujal P; Vernerová Z; Sadowski J; Červenka L
    Physiol Res; 2015; 64(1):25-38. PubMed ID: 25194138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ACE2 and COVID-19: using antihypertensive medications and pharmacogenetic considerations.
    Snyder EM; Johnson BD
    Pharmacogenomics; 2020 Jul; 21(10):695-703. PubMed ID: 32501190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-Converting Enzyme 2 (ACE2) Signaling in Pulmonary Arterial Hypertension: Underpinning Mechanisms and Potential Targeting Strategies.
    Papavassiliou KA; Gogou VA; Papavassiliou AG
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACE2 activation confers endothelial protection and attenuates neointimal lesions in prevention of severe pulmonary arterial hypertension in rats.
    Li G; Liu Y; Zhu Y; Liu A; Xu Y; Li X; Li Z; Su J; Sun L
    Lung; 2013 Aug; 191(4):327-36. PubMed ID: 23652350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The beneficial effects of angiotensin-converting enzyme II (ACE2) activator in pulmonary hypertension secondary to left ventricular dysfunction.
    Chen IC; Lin JY; Liu YC; Chai CY; Yeh JL; Hsu JH; Wu BN; Dai ZK
    Int J Med Sci; 2020; 17(16):2594-2602. PubMed ID: 33029102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are we poised to target ACE2 for the next generation of antihypertensives?
    Ferreira AJ; Raizada MK
    J Mol Med (Berl); 2008 Jun; 86(6):685-90. PubMed ID: 18449520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.